Results 1 to 10 of 10
Page 1 of 1
TypeTitleAuthor(s)YearViews
World gastroenterology organisation practice guideline - hepatitis B September 2008Heathcote, J; Abbas, Z; Alberti, A; Benhamou, Y; Chen, C; Elewaut, A; Ferenci, P; Hui, C; Isakov, V; Janssen, H; Lau, G; Lira, S; Okanoue, T; OnoNita, S; Piratvisuth, T; Rizzetto, M; Sollano, I; Pearman, W; Yeh, CT; Yuen, M; Krabshuis, J200980
 
Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelinesRasenack, J; Poynard, T; Lai, CL; Gane, E; Brown, NA; Heathcote, J2007138
 
76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudineMarcellin, P; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, J; Myers, R; Harb, G; Brown, NA2007119
 
A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysisChan, HLY; Lai, CL; Cho, M; Heathcote, J; Moon, Y-M; Chao, Y-C; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N2006119
 
Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 yearGane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006121
 
Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patientsZeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006126
 
Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 YearBzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N2006159
 
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trialLai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005157
 
Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study)Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005134
 
5-year Follow-up of 998 Chronic Hepatitis B Patients to Determine Long-term Safety of Lamivudine and clinical Consequences of Lamivudine-Resistant MutationsLok, AS; Lai, CL; Leung, N; Yao, GB; Cui, ZY; Schiff, ER; Dienstag, JL; Heathcote, J; Little, NR; Griffiths, DA; Gardner, SD; Castiglia, M2003106
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download